NCT01654276View on ClinicalTrials.gov

Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Gout
Interventions
DRUG

Febuxostat

One 40 mg tablet once a day for 6 months

Trial Locations (1)

75390-8885

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT01654276 - Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome | Biotech Hunter | Biotech Hunter